PubRank

Andrea Balsari

Author PubWeight™ 58.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003 3.40
2 FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009 2.71
3 HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 2003 1.61
4 Apoptosis induction by trastuzumab: possible role of the core biopsy intervention. J Clin Oncol 2005 1.49
5 Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol Ther 2008 1.47
6 Degranulation of paneth cells via toll-like receptor 9. Am J Pathol 2004 1.36
7 Toll-like receptors 3, 4, and 7 are expressed in the enteric nervous system and dorsal root ganglia. J Histochem Cytochem 2009 1.29
8 Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006 1.26
9 Activation of enteroendocrine cells via TLRs induces hormone, chemokine, and defensin secretion. J Immunol 2007 1.15
10 Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4. J Immunol 2008 1.14
11 CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 2008 1.14
12 Activation of smooth muscle and myenteric plexus cells of jejunum via Toll-like receptor 4. J Cell Physiol 2006 1.13
13 Critical role of TLR9 in acute graft-versus-host disease. J Immunol 2008 1.03
14 TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res 2011 1.00
15 HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 2002 1.00
16 HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 2010 0.99
17 CpG-oligodeoxynucleotides induce mobilization of hematopoietic progenitor cells into peripheral blood in association with mouse KC (IL-8) production. J Cell Physiol 2005 0.97
18 FOXP3 expression in tumor cells and implications for cancer progression. J Cell Physiol 2013 0.95
19 Induction of Paneth cell degranulation by orally administered Toll-like receptor ligands. J Cell Physiol 2012 0.93
20 Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005 0.93
21 Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell Oncol 2010 0.93
22 Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res 2008 0.93
23 Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses. J Leukoc Biol 2007 0.91
24 Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev 2011 0.90
25 Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer 2003 0.89
26 Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. Cancer Res 2006 0.88
27 Cross-talk among Toll-like receptors and their ligands. Int Immunol 2008 0.86
28 Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS. Int Immunol 2008 0.86
29 Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J Immunol 2002 0.86
30 High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors. J Transl Med 2013 0.85
31 Stimulation of TLRs by LMW-HA induces self-defense mechanisms in vaginal epithelium. Immunol Cell Biol 2010 0.85
32 Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa. J Immunol 2008 0.85
33 Doxorubicin-induced alopecia is associated with sebaceous gland degeneration. J Invest Dermatol 2006 0.85
34 Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother 2010 0.82
35 Intestinal glucose uptake protects liver from lipopolysaccharide and D-galactosamine, acetaminophen, and alpha-amanitin in mice. Am J Pathol 2009 0.82
36 Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. Int J Cancer 2003 0.82
37 Maspin influences response to doxorubicin by changing the tumor microenvironment organization. Int J Cancer 2013 0.81
38 Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother 2008 0.81
39 Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Int J Cancer 2013 0.80
40 Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 2011 0.80
41 Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. Eur J Cancer 2005 0.80
42 Matured human monocyte-derived dendritic cells (MoDCs) induce expansion of CD4+CD25+FOXP3+ T cells lacking regulatory properties. Immunol Lett 2008 0.79
43 Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation. PLoS One 2013 0.79
44 Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One 2013 0.78
45 EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas. J Cell Physiol 2013 0.78
46 Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate "altered" cells? Oncoimmunology 2012 0.78
47 Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Mol Cancer 2014 0.77
48 Aerosol Delivery in the Treatment of Lung Cancer. Curr Cancer Drug Targets 2015 0.77
49 Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact. Clin Cancer Res 2008 0.77
50 CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. Cancer Immunol Immunother 2004 0.77
51 Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. Eur J Cancer 2006 0.77
52 Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. FEBS Lett 2002 0.77
53 Dansyl C-glucoside as a novel agent against endotoxic shock. ChemMedChem 2010 0.76
54 The HER2 World: Better Treatment Selection for Better Outcome. J Natl Cancer Inst Monogr 2011 0.76
55 Molecular phenotype distinguishes two subsets of gastric low-grade mucosa-associated lymphoid tissue lymphomas. Lab Invest 2002 0.76
56 Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 2002 0.76
57 PET prediction of response to trastuzumab in ErbB2-positive human xenograft model. J Nucl Med 2012 0.75
58 Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model. Breast Cancer Res Treat 2012 0.75
59 Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003 0.75
60 Epithelium-mesenchyme compartment interaction and oncosis on chemotherapy-induced hair damage. Lab Invest 2004 0.75
61 Influence of lignans depletion on murine mammary gland morphology. Nutr Cancer 2010 0.75
62 Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/Neu transgenic mice. J Cell Physiol 2013 0.75